Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
1(50.0%)
Phase 3
1(50.0%)
2Total
Phase 2(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06603285Not Yet Recruiting

A Study to Observe the Safety, Tolerability, and Efficacy of Remodulin

Role: lead

NCT05413655Phase 2Recruiting

A Study of Oral EX039 in Subjects with Mild Alzheimer's Disease

Role: lead

NCT03299829Completed

A Retrospective Study to Assess the Clinical Efficacy and Safety of Trientine in Wilson's Disease Patients

Role: lead

NCT01725646Phase 3Completed

An Efficacy and Safety Study of Omacor® in Taiwanese Hypertriglyceridemic Patients

Role: lead

All 4 trials loaded